|
1
|
Lim M, Xia Y, Bettegowda C and Weller M:
Current state of immunotherapy for glioblastoma. Nat Rev Clin
Oncol. 15:422–442. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaminska B, Czapski B, Guzik R, Król SK
and Gielniewski B: Consequences of IDH1/2 mutations in gliomas and
an assessment of inhibitors targeting mutated IDH proteins.
Molecules. 24(pii): E9682019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stancheva G, Goranova T, Laleva M,
Kamenova M, Mitkova A, Velinov N, Poptodorov G, Mitev V, Kaneva R
and Gabrovsky N: IDH1/IDH2 but not TP53 mutations predict prognosis
in Bulgarian glioblastoma patients. Biomed Res Int.
2014:6547272014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medeiros BC, Fathi AT, DiNardo CD, Pollyea
DA, Chan SM and Swords R: Isocitrate dehydrogenase mutations in
myeloid malignancies. Leukemia. 31:272–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akyerli CB, Yüksel S, Can Ö, Erson-Omay
EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A,
et al: Use of telomerase promoter mutations to mark specific
molecular subsets with reciprocal clinical behavior in IDH mutant
and IDH wild-type diffuse gliomas. J Neurosurg. 128:1102–1114.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hata N, Hatae R, Yoshimoto K, Murata H,
Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M and
Iihara K: Insular primary glioblastomas with IDH mutations:
Clinical and biological specificities. Neuropathology. 37:200–206.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Labussiere M, Boisselier B, Mokhtari K, Di
Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O,
Paterra R, Marie Y, et al: Combined analysis of TERT, EGFR, and IDH
status defines distinct prognostic glioblastoma classes. Neurology.
83:1200–1206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen JE, Lumibao J, Blazek A, Gaskins HR
and Harley B: Hypoxia activates enhanced invasive potential and
endogenous hyaluronic acid production by glioblastoma cells.
Biomater Sci. 6:854–862. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gandhi N and Das GM: Metabolic
reprogramming in breast cancer and its therapeutic implications.
Cells. 8(pii): E892019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cox AG, Tsomides A, Kim AJ, Saunders D,
Hwang KL, Evason KJ, Heidel J, Brown KK, Yuan M, Lien EC, et al:
Selenoprotein H is an essential regulator of redox homeostasis that
cooperates with p53 in development and tumorigenesis. Proc Natl
Acad Sci USA. 113:E5562–E5571. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McArdle A, Pollock N, Staunton CA and
Jackson MJ: Aberrant redox signalling and stress response in
age-related muscle decline: Role in inter- and intra-cellular
signalling. Free Radic Biol Med. 132:50–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singhal SS, Singh SP, Singhal P, Horne D,
Singhal J and Awasthi S: Antioxidant role of glutathione
S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated
signaling. Toxicol Appl Pharmacol. 289:361–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singhal SS, Yadav S, Roth C and Singhal J:
RLIP76: A novel glutathione-conjugate and multi-drug transporter.
Biochem Pharmacol. 77:761–769. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagaprashantha LD, Singhal J, Li H, Warden
C, Liu X, Horne D, Awasthi S, Salgia R and Singhal SS:
2′-Hydroxyflavanone effectively targets RLIP76-mediated drug
transport and regulates critical signaling networks in breast
cancer. Oncotarget. 9:18053–18068. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu N and Du CH: RLIP76 silencing inhibits
cell proliferation and invasion in melanoma cell line A375. Eur Rev
Med Pharmacol Sci. 21:2054–2060. 2017.PubMed/NCBI
|
|
17
|
Wang W, Liu J, Qi J, Zhang J, Zhu Q and
Qin C: RLIP76 increases apoptosis through Akt/mTOR signaling
pathway in gastric cancer. Oncol Rep. 36:2216–2224. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu
YC, Hu GH, Luo C and Chen JX: RLIP76 is overexpressed in human
glioblastomas and is required for proliferation, tumorigenesis and
suppression of apoptosis. Carcinogenesis. 34:916–926. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Q, Qian J, Wang J, Luo C, Chen J, Hu
G and Lu Y: Knockdown of RLIP76 expression by RNA interference
inhibits invasion, induces cell cycle arrest, and increases
chemosensitivity to the anticancer drug temozolomide in glioma
cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Cai Z, Liang Q, Wang Q, Lu Y, Hu
L and Hu G: RLIP76 depletion enhances autophagic flux in U251
cells. Cell Mol Neurobiol. 37:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dao Trong P, Rosch S, Mairbaurl H, Pusch
S, Unterberg A, Herold-Mende C and Warta R: Identification of a
prognostic hypoxia-associated gene set in IDH-mutant glioma. Int J
Mol Sci. 19(pii): E29032018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calvert AE, Chalastanis A, Wu Y, Hurley
LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, et al:
Cancer-associated IDH1 promotes growth and resistance to targeted
therapies in the absence of mutation. Cell Rep. 19:1858–1873. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Wang Q, Cui Y, Liu ZY, Zhao W,
Wang CL, Dong Y, Hou L, Hu G, Luo C, et al: Knockdown of cyclin D1
inhibits proliferation, induces apoptosis, and attenuates the
invasive capacity of human glioblastoma cells. J Neurooncol.
106:473–484. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sharma R, Singhal SS, Cheng J, Yang Y,
Sharma A, Zimniak P, Awasthi S and Awasthi YC: RLIP76 is the major
ATP-dependent transporter of glutathione-conjugates and doxorubicin
in human erythrocytes. Arch Biochem Biophys. 391:171–179. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Derks J, Kulik S, Wesseling P, Numan T,
Hillebrand A, van Dellen E, de Witt Hamer PC, Geurts JJG,
Reijneveld JC, Stam CJ, et al: Understanding cognitive functioning
in glioma patients: The relevance of IDH-mutation status and
functional connectivity. Brain Behav. 9:e012042019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Horbinski C: What do we know about IDH1/2
mutations so far, and how do we use it? Acta Neuropathol.
125:621–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhong H and Yin H: Role of lipid
peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: Focusing
on mitochondria. Redox Biol. 4:193–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gasparovic AC, Milkovic L, Sunjic SB and
Zarkovic N: Cancer growth regulation by 4-hydroxynonenal. Free
Radic Biol Med. 111:226–234. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang PF, Song HW, Cai HQ, Kong LW, Yao K,
Jiang T, Li SW and Yan CX: Preoperative inflammation markers and
IDH mutation status predict glioblastoma patient survival.
Oncotarget. 8:50117–50123. 2017.PubMed/NCBI
|
|
33
|
Zhang Y, Song X, Gong W, Zhu Z, Liu X, Hou
Q, Sun Y, Chai J, Zou L and Guan J: RLIP76 blockade by siRNA
inhibits proliferation, enhances apoptosis, and suppresses invasion
in HT29 colon cancer cells. Cell Biochem Biophys. 71:579–585. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singhal SS, Singhal J, Yadav S, Sahu M,
Awasthi YC and Awasthi S: RLIP76: A target for kidney cancer
therapy. Cancer Res. 69:4244–4251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Singhal SS, Nagaprashantha L, Singhal P,
Singhal S, Singhal J, Awasthi S and Horne D: RLIP76 inhibition: A
promising developmental therapy for neuroblastoma. Pharm Res.
34:1673–1682. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Parker SJ and Metallo CM: Metabolic
consequences of oncogenic IDH mutations. Pharmacol Ther. 152:54–62.
2015. View Article : Google Scholar : PubMed/NCBI
|
